Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Breast Cancer Research : BCR|July 6, 2012
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
European Journal of Human Genetics : EJHG|January 21, 2016
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS studyAmandine I Garcia, Monique Buisson, Francesca Damiola, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
JAMA Ophthalmology|June 18, 2025
Uveal Melanoma and the Lynch Syndrome Tumor SpectrumAnaïs Le Ven, Marie-Charlotte Villy, André Bortolini Silveira, et al.
Pageof 11